Myriad Non Current Assets Total vs Total Assets Analysis
MYGN Stock | USD 16.28 0.11 0.68% |
Myriad Genetics financial indicator trend analysis is infinitely more than just investigating Myriad Genetics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Myriad Genetics is a good investment. Please check the relationship between Myriad Genetics Non Current Assets Total and its Total Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.
Non Current Assets Total vs Total Assets
Non Current Assets Total vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Myriad Genetics Non Current Assets Total account and Total Assets. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Myriad Genetics' Non Current Assets Total and Total Assets is 0.86. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Total Assets in the same time period over historical financial statements of Myriad Genetics, assuming nothing else is changed. The correlation between historical values of Myriad Genetics' Non Current Assets Total and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Myriad Genetics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Non Current Assets Total i.e., Myriad Genetics' Non Current Assets Total and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.86 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Total Assets
Total assets refers to the total amount of Myriad Genetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Myriad Genetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Myriad Genetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Myriad Genetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.At this time, Myriad Genetics' Tax Provision is very stable compared to the past year. As of the 28th of November 2024, Issuance Of Capital Stock is likely to grow to about 123.5 M, while Selling General Administrative is likely to drop about 468.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 690.6M | 678.4M | 753.2M | 414.1M | Depreciation And Amortization | 62.8M | 55.9M | 61.9M | 65.0M |
Myriad Genetics fundamental ratios Correlations
Click cells to compare fundamentals
Myriad Genetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Myriad Genetics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.6B | 1.4B | 1.3B | 1.2B | 1.1B | 670.7M | |
Other Current Liab | 82.3M | 104.9M | 122.9M | 60.1M | 109.3M | 114.8M | |
Total Current Liabilities | 117.8M | 145.9M | 204.3M | 137.2M | 155.9M | 163.7M | |
Total Stockholder Equity | 1.1B | 881M | 967.8M | 885.8M | 783.2M | 529.5M | |
Property Plant And Equipment Net | 57.3M | 100.4M | 125.3M | 187.3M | 180.6M | 189.6M | |
Net Debt | 140.3M | (117M) | (166.1M) | 88.1M | 20M | 21M | |
Retained Earnings | 25.6M | (227M) | (254.2M) | (366.2M) | (629.5M) | (598.0M) | |
Accounts Payable | 33.3M | 20.5M | 29.6M | 28.8M | 25.8M | 17.0M | |
Cash | 93.2M | 117M | 258.4M | 56.9M | 132.1M | 92.1M | |
Non Current Assets Total | 1.2B | 1.0B | 835.9M | 924.1M | 832.9M | 874.5M | |
Common Stock Shares Outstanding | 76M | 74.8M | 78M | 80.6M | 82.8M | 75.0M | |
Non Current Liabilities Total | 356M | 224.8M | 148.6M | 175.7M | 207.4M | 217.8M | |
Other Current Assets | 46.4M | 122.1M | 38.4M | 20.4M | 36.4M | 55.5M | |
Other Stockholder Equity | 1.1B | 1.1B | 1.2B | 1.3B | 1.4B | 1.5B | |
Total Liab | 473.8M | 537.8M | 352.9M | 312.9M | 363.3M | 381.5M | |
Total Current Assets | 348.6M | 389.4M | 484.8M | 274.6M | 313.6M | 306.6M | |
Net Receivables | 138.6M | 89.5M | 91.3M | 101.6M | 114.3M | 61.5M | |
Short Term Investments | 43.7M | 33.7M | 81.4M | 58M | 8.8M | 8.4M | |
Inventory | 31.4M | 27.1M | 15.3M | 20.1M | 22M | 23.1M | |
Good Will | 417.2M | 329.2M | 239.2M | 286.8M | 287.4M | 245.9M | |
Intangible Assets | 684.7M | 578.8M | 404.1M | 379.7M | 349.5M | 339.7M |
Pair Trading with Myriad Genetics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.Moving together with Myriad Stock
0.75 | FDMT | 4D Molecular Therapeutics | PairCorr |
0.86 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.96 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Myriad Stock
0.91 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.87 | NAMS | NewAmsterdam Pharma | PairCorr |
0.66 | PMVP | Pmv Pharmaceuticals | PairCorr |
0.58 | PHVS | Pharvaris BV | PairCorr |
0.47 | PLRX | Pliant Therapeutics | PairCorr |
The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.
The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.